Viking Therapeutics Investor Relations Material
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics to treat metabolic, endocrine and other central nervous system disorders. The company focuses on treatments for patients with liver disease, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease and fibrosis; diabetes; thyroid diseases; and those suffering from adrenoleukodystrophy (ALD) and X-linked adrenoleukodystrophy (X-ALD). For NASH, it develops VK2809 - an orally available tissue and receptor-subtype selective agonist of thyroid hormone receptor beta (TRß) which is also in Phase IIb clinical trials for the treatment of patients with biopsy-confirmed NAFLD. Additional programs include VK0603 and VK0612 - orally available non-steroidal selective androgen receptor modulator drugs that are in Phase IIb clinical trials for the treatment of patients recovering from hip fractures; VK0612 is in Phase IIc clinical trials for type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Diego, California.
Key slides for Viking Therapeutics Inc
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
🇺🇸 United States